10-K: Contineum Therapeutics Reports 2025 Results, Advances Pipeline

Contineum Therapeutics, Inc. reported a net loss of $59.978 million for 2025, initiated a Phase 2 trial for PIPE-791 in IPF, and saw its partnered PIPE-307 fail its primary efficacy endpoints in RRMS.

Summary

• Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on Neuroscience, Inflammation, and Immunology (NI&I) indications.
• The company's wholly-owned lead asset, PIPE-791, a novel LPA1R inhibitor, is in development for Idiopathic Pulmonary Fibrosis (IPF) and chronic pain (osteoarthritic pain and chronic low back pain).
• Positive top-line data from the Phase 1b PET trial for PIPE-791 was reported in September 2025, affirming planned dose selection for the Phase 2 IPF trial.
• A global Phase 2 PROPEL-IPF trial for PIPE-791 in IPF was initiated in December 2025, with an estimated enrollment of 324 subjects and projected completion in June 2028.
• Enrollment for the Phase 1b chronic pain trial for PIPE-791 (COAP/CLBP) was completed in Q4 2025, with top-line data anticipated in Q2 2026.
• The second drug candidate, PIPE-307, a selective M1R inhibitor, is being developed in collaboration with Johnson & Johnson (J&J) for depression and relapse-remitting multiple sclerosis (RRMS).
• J&J began recruiting an estimated 124 adult participants for the Phase 2 Moonlight-1 trial of PIPE-307 (JNJ-89495120) for Major Depressive Disorder (MDD) in December 2024.
• Top-line data from the Phase 2 VISTA trial of PIPE-307 for RRMS was reported in November 2025, showing acceptable safety and tolerability but failing to meet its prespecified primary and secondary efficacy endpoints.
• A strategic decision was made to defer further clinical development of PIPE-791 for Progressive MS (PrMS) and CTX-343 (a peripherally-restricted LPA1R antagonist) until additional funding is obtained.
• The net loss for the year ended December 31, 2025, was $59.978 million, an increase from $42.258 million in 2024.
• Research and development expenses increased by $13.1 million to $51.522 million in 2025 from $38.422 million in 2024.
• General and administrative expenses increased by $4.0 million to $16.537 million in 2025 from $12.472 million in 2024.
• Cash, cash equivalents, and marketable securities totaled $262.9 million as of December 31, 2025.
• The company raised $19.0 million net from an At-The-Market (ATM) offering and $93.0 million net from a follow-on public offering in 2025.
• Management believes existing cash, cash equivalents, and marketable securities will be sufficient to meet anticipated operating expenses and capital expenditure requirements through at least the next 12 months.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed filing with significant financial burn and a major clinical setback for a partnered asset (PIPE-307 in RRMS), partially offset by progress in other pipeline candidates (PIPE-791 in IPF and chronic pain) and successful capital raises. The deferral of other programs due to funding needs indicates ongoing financial challenges despite recent raises.

Positives

• Reported positive top-line data from the Phase 1b PET trial for PIPE-791 in September 2025, affirming planned dose selection for the Phase 2 IPF trial.
• Initiated a global Phase 2 PROPEL-IPF trial for PIPE-791 in IPF in December 2025.
• Completed enrollment for the Phase 1b chronic pain trial for PIPE-791 (COAP/CLBP) in Q4 2025.
• J&J initiated a Phase 2 Moonlight-1 trial for PIPE-307 in MDD in December 2024, indicating continued partnership activity for this asset.
• The Phase 2 VISTA trial of PIPE-307 for RRMS demonstrated acceptable safety and tolerability.
• Maintained a strong cash, cash equivalents, and marketable securities balance of $262.9 million as of December 31, 2025.
• Successfully raised $19.0 million net from an At-The-Market (ATM) offering and $93.0 million net from a follow-on public offering in 2025, bolstering liquidity.
• Management believes existing capital is sufficient to fund operations for at least the next 12 months.
• PIPE-791 is designed to avoid hepatobiliary toxicity observed with previous LPA1R compounds, showing potential for a differentiated safety profile.
• PIPE-791 demonstrated high oral bioavailability, high metabolic stability, low plasma protein binding, and long receptor residence time in preclinical studies.
• The company believes PIPE-307 is the most advanced selective M1R antagonist in clinical development.
• Adopted the 2026 Employment Inducement Equity Incentive Plan in January 2026 to attract and retain qualified personnel.

Negatives

• Net loss increased to $59.978 million in 2025 from $42.258 million in 2024, indicating a higher burn rate.
• Research and development expenses increased by $13.1 million in 2025, contributing to the increased net loss.
• General and administrative expenses increased by $4.0 million in 2025.
• Interest income decreased by $0.7 million in 2025.
• The Phase 2 VISTA trial of PIPE-307 for RRMS did not meet its prespecified primary and secondary efficacy endpoints, representing a significant clinical setback for a partnered asset.
• Strategic decision to defer further clinical development of PIPE-791 for Progressive MS (PrMS) and CTX-343 until additional funding is obtained, indicating capital constraints for certain programs.
• J&J has sole discretion on whether to further develop PIPE-307 for RRMS, MDD, or any other indication, limiting the company's control over this asset's future.
• The company has a limited operating history and no products approved for commercial sale.

Risks

• Heavy dependence on the success of PIPE-791 and PIPE-307, both in early clinical development, with no guarantee of regulatory approval or commercialization.
• Clinical drug development is a lengthy, expensive, and risky process with uncertain timelines and outcomes; earlier preclinical/clinical results may not be predictive of future success.
• The regulatory approval processes of the FDA and comparable foreign authorities are unpredictable, lengthy, and time-consuming, and failure to obtain approval would substantially harm the business.
• May not be successful in identifying and developing additional drug candidates or indications due to limited resources and capital, potentially leading to incorrect prioritization decisions.
• Clinical trials conducted outside the United States may not have data accepted by the FDA or other regulatory authorities, leading to development delays and increased costs.
• Significant and anticipated increases in operating expenses for the foreseeable future, making sustained profitability uncertain and potentially leading to a decline in common stock market value.
• Requires significant additional capital to complete the development and commercialization of PIPE-791 and other drug candidates, and adequate financing may not be available on acceptable terms.
• The J&J License Agreement may not result in the successful development of PIPE-307, harming the company's business, financial condition, and results of operations.
• Inability to obtain, maintain, and enforce intellectual property protection for technology and drug candidates, or if the scope of protection is insufficient, competitors could commercialize similar products.
• Reliance on third-party Contract Manufacturing Organizations (CMOs) for clinical and potential commercial supplies, exposing the company to supply chain disruptions, quality control issues, and compliance risks (e.g., potential impact of the BIOSECURE Act on Chinese CMOs like WuXi AppTec).
• Reliance on third parties (CROs) to conduct clinical trials; failure to successfully carry out contractual duties, comply with regulatory requirements, or meet deadlines could substantially harm the business.
• Future success depends on the ability to retain key personnel and attract, retain, and motivate qualified personnel in a highly competitive environment.
• Significant competition from biotechnology, pharmaceutical, and medical device companies, which could lead to operating results suffering if the company fails to compete effectively.
• Even if PIPE-791 or PIPE-307 receives marketing approval, it may fail to achieve market acceptance by physicians, patients, and third-party payors.
• Lack of sales, marketing, or distribution capabilities or experience, requiring significant investment or successful collaborations for commercialization.
• Potential product liability lawsuits could cause substantial liabilities and limit commercialization.
• Changes in healthcare legislation and regulations (e.g., Inflation Reduction Act, executive orders on drug pricing) may increase costs, reduce reimbursement, and adversely affect product pricing.
• Unstable or unfavorable global economic conditions and an uncertain geopolitical environment could adversely affect business, financial condition, results of operations, and prospects.
• Ability to use net operating loss carryforwards (NOLs) and certain other tax attributes may be limited by ownership changes under IRC Sections 382 and 383.
• Risk of system failures, security breaches, or loss of proprietary information, potentially leading to liability, reputational harm, and development delays.
• The dual series structure of Class A and Class B common stock may limit the ability of Class A holders to influence corporate matters.
• Delaware law and provisions in the company's certificate of incorporation and bylaws could make a merger, tender offer, or proxy contest difficult, potentially depressing the trading price of common stock.
• Exclusive forum provisions in the certificate of incorporation could limit stockholders' ability to obtain a favorable judicial forum for disputes.

Future Outlook

The company expects operating expenses to significantly increase for the foreseeable future as it continues to develop, conduct clinical trials, and seek regulatory approvals for its drug candidates, expand its pipeline, operations, and intellectual property portfolio, and potentially launch commercial activities. It anticipates financing these operations through public and private equity sales, debt financings, or other commercial arrangements, including income from collaborations. The Phase 2 PROPEL-IPF trial for PIPE-791 is projected to complete in June 2028, and top-line data from the PIPE-791 Phase 1b chronic pain trial is expected in Q2 2026. Clinical development for PIPE-791 in PrMS and CTX-343 is deferred until specific funding is secured. J&J retains sole discretion over the future development of PIPE-307 for RRMS, MDD, or other indications.

Management Comments

• "We are a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of NI&I indications with significant unmet need."
• "We believe our two clinical-stage, internally-discovered drug candidates, PIPE-791 and PIPE-307, will have broad applicability across multiple NI&I indications."
• "Specifically, based on its high bioavailability, high selectivity, low plasma protein binding, and long receptor residence time, we believe PIPE-791 has the potential to be a differentiated LPA1R therapy."
• "We believe PIPE-307 is the most advanced selective M1R antagonist in clinical development."
• "Our mission is to significantly impact the clinical disability associated with NI&I diseases with small molecules designed to modulate innate pathways to restore function."
• "Management believes the Company's existing cash, cash equivalents, and marketable securities will be sufficient to support its operations for at least 12 months from the date of this Annual Report on Form 10-K."

Industry Context

StockSavvy.ai notes that the biopharmaceutical industry is characterized by intense competition, rapid technological advancements, and robust intellectual property defense. Contineum Therapeutics operates within this challenging landscape, facing established pharmaceutical giants, specialized biotech firms, and academic institutions. The market for Idiopathic Pulmonary Fibrosis (IPF) is substantial, with existing FDA-approved therapies like pirfenidone and nintedanib generating approximately $4 billion in combined global sales in 2022, but these are limited by tolerability and dosing issues. The company's PIPE-791 aims to differentiate itself with a once-daily dosing and improved tolerability profile. In chronic pain and depression, the market is saturated with numerous generic and branded treatments, and many competitors are also developing new drug candidates. The clinical failure of PIPE-307 in Relapse-Remitting Multiple Sclerosis (RRMS) underscores the high-risk nature of drug development, particularly in areas with existing treatments that target different mechanisms. The strategic decision to defer less-funded programs (PIPE-791 for PrMS and CTX-343) is a common and prudent approach for biotech companies managing capital in a competitive and uncertain R&D environment.

Comparison to Industry Standards

• PIPE-791 is being developed as a once-daily (QD) therapy at low doses (<10 mg) for IPF, aiming to improve upon currently approved IPF therapies (pirfenidone, nintedanib, nerandomilast) which require multiple-daily dosing regimens and are associated with tolerability and compliance issues.
• PIPE-791 is designed to avoid hepatobiliary toxicity, a significant side effect observed with previous LPA1R antagonists like BMS-986020, by minimizing inhibition of bile acid transporters (BSEP IC50 > 20 µM for PIPE-791 vs. 68% inhibition at 10 µM for BMS-986020 in SCHH assay).
• Preclinical studies showed PIPE-791 achieved high LPA1R occupancy for over 24 hours after a single oral dose, a potentially differentiated pharmacokinetic profile compared to other LPA1R antagonists like BMS-986278, BMS-986020, and AMG-670.
• The Phase 2 VISTA trial of PIPE-307 for RRMS did not meet its primary and secondary efficacy endpoints, contrasting with over 20 FDA-approved disease-modifying therapies (DMTs) for RRMS that focus on immune modulation, none of which directly promote remyelination, which PIPE-307 aimed to address.
• PIPE-307 is positioned as the most advanced selective M1R antagonist in clinical development for depression, a market with numerous approved antidepressant drugs (SSRIs, SNRIs, antipsychotics, mood stabilizers) that often have limitations in efficacy and side effect profiles.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings. May become involved in legal proceedings arising in the ordinary course of business from time to time.

Related Party Transactions

• Entered into a license agreement with Janssen Pharmaceutica NV, a Johnson & Johnson (J&J) company, in February 2023 for PIPE-307. Received an upfront payment of $50.0 million and is eligible for up to $1.0 billion in milestone payments and tiered royalties. Additionally, received a $25.0 million equity investment from Johnson & Johnson Innovation – JJDC, Inc., an affiliate of J&J.

Stakeholder Impact

• Shareholders: Experienced dilution from recent equity offerings and face potential future dilution from additional capital raises. The market price of common stock may be volatile due to clinical trial results and market conditions. The dual-class stock structure may limit the influence of Class A common stockholders.
• Employees: Benefit from new equity incentive plans (2024 Equity Incentive Plan, 2024 Employee Stock Purchase Plan, 2026 Employment Inducement Equity Incentive Plan) designed to attract, retain, and motivate talent. Anticipated business growth may lead to increased headcount.
• Customers/Patients: Potential for new therapies in NI&I indications, particularly IPF and chronic pain with PIPE-791. However, the failure of PIPE-307 in RRMS represents a setback for patients awaiting new treatments in that area.
• Creditors: Increased net losses and the ongoing need for additional financing could impact the company's long-term creditworthiness, although the current cash position is strong.
• Suppliers/CMOs: Continued reliance on third-party contract manufacturers and contract research organizations. Potential impact of U.S. legislation like the BIOSECURE Act on relationships with Chinese CMOs (e.g., WuXi AppTec) could affect supply chains and costs.

Next Steps

• Anticipate top-line data from the PIPE-791 Phase 1b chronic pain trial in the second quarter of 2026.
• Continue the global Phase 2 PROPEL-IPF trial for PIPE-791, with projected completion in June 2028.
• J&J will determine whether to further develop PIPE-307 for RRMS, MDD, or any other indication, following the Phase 2 VISTA trial results.
• Complete non-clinical activities for CTX-343 to support a potential regulatory filing for a Phase 1 trial in 2026, contingent on obtaining additional funding.
• Seek additional funding through equity offerings, debt financings, or other commercial arrangements to support product development and future commercialization efforts.
• If PIPE-791 receives marketing approval, plans to commercialize it in the United States by developing its own sales and marketing organization.
• Intends to establish commercialization strategies for PIPE-791 outside the United States, primarily through collaborations with other companies.

Key Dates

Recommendation

StockSavvy.ai recommends a 'Hold' for Contineum Therapeutics. While the company has a solid cash position and is progressing its lead asset, PIPE-791, into a Phase 2 IPF trial with promising early data, the significant clinical setback of PIPE-307 in RRMS is a material negative. The deferral of other pipeline programs due to funding needs highlights ongoing capital requirements and inherent risks in early-stage biotech. Investors should await further clinical data from PIPE-791 and clarity on J&J's future development plans for PIPE-307 before considering a more aggressive stance.

Keywords

Contineum Therapeutics, PIPE-791, PIPE-307, LPA1R antagonist, M1R inhibitor, Idiopathic Pulmonary Fibrosis, IPF, Chronic Pain, Major Depressive Disorder, MDD, Relapse-Remitting Multiple Sclerosis, RRMS, Clinical-stage biopharmaceutical, Neuroscience, Inflammation, Immunology, Drug development, Clinical trials, SEC filing, 10-K, Biotechnology, Pharmaceutical